Myriad to Buy Back $100M in Shares

Mar 02, 2011

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market Tuesday that its board of directors has authorized a $100 million stock repurchase program.

The latest buyback is the firm's third $100 million share repurchase program.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Scan

Microsoft, But the Brain, Too

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

Been Reclassified

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

This Week in Cell

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

Pursuit of a Cancer Vaccine

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

Featured White Papers

Potential Pitfalls to Life Science Product Launch

Freeze-drying - a manufacturing approach to increase the stability of in vitro diagnostic (IVD) assays

Point of Care Testing Using Smartphone Diagnostic Readers - Download FAQ Guide

Contract Manufacturing in Biotech: Turning Your Supply Chain Into a Competitive Differentiator

Oct

23

Featured Webinar

Perspectives on Small RNA Sequencing: Challenges and Complications of Small RNA Library Prep

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov

29

Featured Webinar

Glass or Polymer? A Comparison for Use in In Vitro Diagnostic Biochips

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

Main menu